- Home
- RCUS vs AOD Comparison
RCUS vs AOD Comparison
Compare RCUS & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- AOD
- Stock Information
- Founded
- RCUS 2015
- AOD 2006
- Country
- RCUS United States
- AOD United Kingdom
- Employees
- RCUS N/A
- AOD N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- AOD Investment Managers
- Sector
- RCUS Health Care
- AOD Finance
- Exchange
- RCUS Nasdaq
- AOD Nasdaq
- Market Cap
- RCUS 906.4M
- AOD 862.4M
- IPO Year
- RCUS 2018
- AOD N/A
- Fundamental
- Price
- RCUS $9.32
- AOD $8.95
- Analyst Decision
- RCUS Buy
- AOD
- Analyst Count
- RCUS 8
- AOD 0
- Target Price
- RCUS $20.86
- AOD N/A
- AVG Volume (30 Days)
- RCUS 721.6K
- AOD 423.5K
- Earning Date
- RCUS 08-07-2025
- AOD 01-01-0001
- Dividend Yield
- RCUS N/A
- AOD 12.95%
- EPS Growth
- RCUS N/A
- AOD 213.63
- EPS
- RCUS N/A
- AOD 1.93
- Revenue
- RCUS $141,000,000.00
- AOD $72,962,082.00
- Revenue This Year
- RCUS N/A
- AOD N/A
- Revenue Next Year
- RCUS $28.73
- AOD N/A
- P/E Ratio
- RCUS N/A
- AOD $4.44
- Revenue Growth
- RCUS N/A
- AOD N/A
- 52 Week Low
- RCUS $6.50
- AOD $6.99
- 52 Week High
- RCUS $18.98
- AOD $9.14
- Technical
- Relative Strength Index (RSI)
- RCUS 55.03
- AOD 55.29
- Support Level
- RCUS $9.14
- AOD $8.99
- Resistance Level
- RCUS $10.34
- AOD $9.10
- Average True Range (ATR)
- RCUS 0.48
- AOD 0.07
- MACD
- RCUS 0.07
- AOD -0.01
- Stochastic Oscillator
- RCUS 48.91
- AOD 40.38
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.